Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a culturally tailored online program get more black cancer survivors tested for genetic risks?

NCT ID NCT07436078

Knowledge-focused Sponsor: Barbara Ann Karmanos Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to help African American cancer survivors learn about and get genetic testing for hereditary cancer risks. Researchers are adapting an online educational program to be culturally relevant, with input from community leaders and genetics experts. About 85 participants from Detroit will take surveys before and after the program, and at 3 months, to see if it increases their use of genetic counseling and testing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
culturally adapted online genetic counseling and testing information
What this could lead to
If successful, this could point toward a way to increase genetic testing among African American cancer survivors, potentially catching hereditary cancer risks earlier.
What could go wrong
This is a small, early-stage study (85 participants) focused on education and uptake, not on direct health outcomes. Results may not apply to other groups or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 85 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants enrolled in Detroit Research on Cancer Survivors (Detroit ROCS) * Diagnosis of Primary Breast, prostate, or colorectal cancer on or after 1/1/2013 * have received or currently receiving care at Karmanos Cancer Institute * meet one or more of the National Comprehensive Cancer Network (NCCN) guidelines for cancer genetic testing as described below Female breast 1. personal diagnosis at age ≤50 2. personal history of the triple-negative subtype 3. at least 1 close (first- or second-degree) relative diagnosed with breast cancer at age \<50 4. at least 1 close relative diagnosed with ovarian cancer 5. 2+ close relatives diagnosed with breast or prostate cancer 6. age \<50 AND another primary breast cancer at any age 7. 2+ primary breast cancers at any age OR Prostate 1. personal history of high-risk or very high-risk prostate cancer 2. personal history of regional or metastatic prostate cancer 3. personal history of less than high-risk prostate cancer with a suggestive family history (i.e., father or brother or multiple relatives with prostate cancer diagnosed at age \<60; at least 1 relative with breast, ovarian, or pancreatic cancer; or at least 1 relative with colorectal, ovarian, pancreatic, or kidney cancer) OR Colorectal 1. personal diagnosis at age ≤50 2. at least 1 close relative diagnosed with HNPCC at age \<50 3. at least 2 close relatives diagnosed with an HNPCC cancer at any age 4. colorectal and \>=1 primary endometrial, ovarian, gastric, pancreatic, or prostate Exclusion Criteria: * Previous genetic counseling and/or testing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer colorectal carcinoma colorectal neoplasm female breast carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal carcinoma Female breast cancer Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.